Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer

Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced... Clin Transl Oncol (2017) 19:1117–1124 DOI 10.1007/s12094-017-1647-9 RESEARCH AR TIC L E Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer 1,2 1,2 1,2 1,2 1,2 2,3 • • • • • • K. Zhou F. Wen P. Zhang J. Zhou H. Chen H. Zheng 1,2 1,2 Y. Yang Q. Li Received: 23 November 2016 / Accepted: 13 March 2017 / Published online: 28 March 2017 Federacio ´ n de Sociedades Espan ˜ olas de Oncologı ´a (FESEO) 2017 Abstract cost-effective ratio was $18,223.75/QALY for second-line Purpose Second-line chemotherapy has been shown to chemotherapy versus BSC, which was below the threshold benefit patients with advanced gastric cancer (AGC), of 39 the per capita GDP of China, $23,970.00. extending the overall survival (OS) and progression-free Conclusion Second-line chemotherapy was an optimal survival (PFS). This study aimed to assess the efficacy and strategy for elderly AGC patients in China from the effi- cost-effectiveness of second-line treatment for elderly cacy and cost-effectiveness perspective. patients with AGC. Methods Medical records and follow-up information of Keywords Cost-effectiveness  Advanced gastric cancer elderly patients (C70 years) with AGC who received second- Elderly  Second-line chemotherapy line chemotherapy were collected. A Markov http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Translational Oncology Springer Journals

Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer

Loading next page...
 
/lp/springer_journal/efficacy-and-cost-effectiveness-of-second-line-chemotherapy-in-elderly-Fuy2G0ZDEf
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Federación de Sociedades Españolas de Oncología (FESEO)
Subject
Medicine & Public Health; Oncology
ISSN
1699-048X
eISSN
1699-3055
D.O.I.
10.1007/s12094-017-1647-9
Publisher site
See Article on Publisher Site

Abstract

Clin Transl Oncol (2017) 19:1117–1124 DOI 10.1007/s12094-017-1647-9 RESEARCH AR TIC L E Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer 1,2 1,2 1,2 1,2 1,2 2,3 • • • • • • K. Zhou F. Wen P. Zhang J. Zhou H. Chen H. Zheng 1,2 1,2 Y. Yang Q. Li Received: 23 November 2016 / Accepted: 13 March 2017 / Published online: 28 March 2017 Federacio ´ n de Sociedades Espan ˜ olas de Oncologı ´a (FESEO) 2017 Abstract cost-effective ratio was $18,223.75/QALY for second-line Purpose Second-line chemotherapy has been shown to chemotherapy versus BSC, which was below the threshold benefit patients with advanced gastric cancer (AGC), of 39 the per capita GDP of China, $23,970.00. extending the overall survival (OS) and progression-free Conclusion Second-line chemotherapy was an optimal survival (PFS). This study aimed to assess the efficacy and strategy for elderly AGC patients in China from the effi- cost-effectiveness of second-line treatment for elderly cacy and cost-effectiveness perspective. patients with AGC. Methods Medical records and follow-up information of Keywords Cost-effectiveness  Advanced gastric cancer elderly patients (C70 years) with AGC who received second- Elderly  Second-line chemotherapy line chemotherapy were collected. A Markov

Journal

Clinical and Translational OncologySpringer Journals

Published: Mar 28, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off